Home > Insider Trading > Filing (0000899243-19-006455)

Filing Details

Accession Number:: 0000899243-19-006455
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-03-06 16:45:31
Reporting Period:: 2019-03-04

Accepted Time:: 2019-03-06 16:45:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1751299	Kaleido Biosciences Inc.	KLDO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	Yes	No	Yes	No
1400240	Flagship Pioneering Inc.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1627639	Flagship Ventures Fund V, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1677345	Flagship Ventures Opportunities Fund I, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1724575	Flagship Ventures Fund V General Partner Llc	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	Yes	No	Yes	No
1724959	Flagship Venturelabs V Llc	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1725000	Nutritional Health Side Fund, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1725001	Nutritional Health Disruptive Innovation Fund, L.p.	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1725004	Flagship Ventures Opportunities Fund I General Partner Llc	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No
1768987	Flagship Venturelabs V Manager Llc	55 Cambridge Parkway, Suite 800E Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-03-04	1,545,852	$0.00	1,545,852	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	4,637,555	$0.00	4,637,555	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	426,240	$0.00	1,972,092	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	639,360	$0.00	639,360	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	321,337	$0.00	2,293,429	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	964,010	$0.00	5,601,565	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	1,285,347	$0.00	1,285,347	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	625,625	$0.00	6,227,190	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	625,625	$0.00	1,910,972	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	266,667	$15.00	2,560,096	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	333,333	$15.00	6,560,523	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2019-03-04	333,333	$15.00	2,244,305	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-03-04	3,091,704	$0.00	1,545,852	$0.00
Common Stock	Series A Preferred Stock	Disposition	2019-03-04	9,275,111	$0.00	4,637,555	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2019-03-04	852,480	$0.00	426,240	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2019-03-04	1,278,720	$0.00	639,360	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-03-04	642,674	$0.00	321,337	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-03-04	1,928,021	$0.00	964,010	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-03-04	2,570,694	$0.00	1,285,347	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-03-04	1,251,251	$0.00	625,625	$0.00
Common Stock	Series C Preferred Stock	Disposition	2019-03-04	1,251,251	$0.00	625,625	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,500,000	Indirect	See Footnote

Footnotes

Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of these entities and Noubar B. Afeyan, Ph.D. may be deemed to share voting and investment power with respect to all shares held by VentureLabs V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering.
Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering.
Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Health Side Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering.
Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering.
Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.